Revenue: As of FY2026 Q1, the actual value is USD 8.315 M, beating the estimate of USD 5.836 M.EPS: As of FY2026 Q1, the actual value is USD -0.14, beating the estimate of USD -0.1871.<h4>Revenue</h4>Total revenue for AbCellera Biologics Inc. was $8.3 million in Q1 2026, an increase from $4.2 million in Q1 2025.Research fees contributed $8.124 million in Q1 2026, up from $4.068 million in Q1 2025.Licensing and royalty revenue was $0.191 million in Q1 2026, compared to $0.167 million in Q1 2025.<h4>Operating Expenses</h4>Research &amp; Development (R&amp;D) expenses were $46.662 million in Q1 2026, an increase from $42.496 million in Q1 2025.Sales, General, &amp; Administrative (SG&amp;A) expenses decreased to $12.334 million in Q1 2026 from $19.068 million in Q1 2025.Depreciation and amortization expenses were $6.838 million in Q1 2026, compared to $5.331 million in Q1 2025.Total operating expenses were $65.834 million in Q1 2026, down from $66.895 million in Q1 2025.<h4>Profitability</h4>Loss from operations was - $57.519 million in Q1 2026, an improvement from - $62.660 million in Q1 2025.Net loss for AbCellera Biologics Inc. was - $43.2 million in Q1 2026, compared to a net loss of - $45.6 million in Q1 2025.Comprehensive loss was - $41.350 million in Q1 2026, compared to - $48.241 million in Q1 2025.<h4>Liquidity and Cash Flow</h4>AbCellera Biologics Inc. ended Q1 2026 with approximately $655 million in total available liquidity.This includes $531 million of total cash, cash equivalents, and marketable securities and approximately $124 million in available non-dilutive government funding.Net cash used in operating activities was - $33.523 million in Q1 2026, compared to - $11.554 million in Q1 2025.Net cash used in investing activities was - $25.081 million in Q1 2026, compared to net cash provided by investing activities of $7.935 million in Q1 2025.Net cash provided by financing activities was $7.192 million in Q1 2026, compared to $5.970 million in Q1 2025.Cash and cash equivalents and restricted cash at the end of Q1 2026 totaled $103.799 million, down from $186.556 million at the end of Q1 2025.<h4>Operational Metrics</h4>As of March 31, 2026, AbCellera Biologics Inc. had 40 partner-led programs with downstream participation, a decrease from 44 on December 31, 2025.Of these, 5 programs were in the clinic, consistent with December 31, 2025, while 35 programs were in discovery or preclinical development, down from 39.The company held downstream stakes in 14 molecules in the clinic as of March 31, 2026, unchanged from December 31, 2025.ABCL635 demonstrated a favorable tolerability profile with no observed liver toxicity and achieved potent and sustained reductions in biomarkers of target engagement in its Phase 1 clinical trial, with its pharmacokinetic profile supporting potential once-monthly dosing.<h4>Outlook / Guidance</h4>AbCellera Biologics Inc. is focused on delivering data readouts for its clinical programs through 2026, including an anticipated efficacy readout from the ABCL635 Phase 2 data in Q3 2026 and ABCL575 data in Q4 2026.The company plans to advance ABCL688 and ABCL386 into IND-enabling studies and select at least one additional development candidate.For 2027, AbCellera Biologics Inc. expects late-stage development for ABCL635, initiation of ABCL635 Phase 2 in oncology VMS, and IND submissions for ABCL688 and ABCL386, while projecting 1-2 new development candidates annually from its pipeline of over 20 discovery programs.

Abcellera Biologics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 8.315 M